Stock LIPO LIPELLA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Lipella Pharmaceuticals Inc.

Equities

LIPO

US53630L1008

Delayed Nasdaq
Other stock markets
 13:39:06 2024-05-17 EDT 		5-day change 1st Jan Change
0.78 USD +2.31% Intraday chart for Lipella Pharmaceuticals Inc. +6.56% -23.53%
05-09 Lipella Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-17 Lipella Pharmaceuticals Inc. Appoints Jason Hafron and Pradeep Tyagi to Scientific Advisory Board CI

Evolution of the average Target Price on Lipella Pharmaceuticals Inc.

Price target over the last 5 years

History of analyst recommendation changes

a6da127837f04e4084c3c00e7b836a5.vn4NOmaHhGYg4DFRDkpftIYseBNsvB14D2Jxj-ed55I.iE58AxHXxSoS12A1RD4a49V1OXoP01dBfRsW577Z0aPTO0BTXt_eLg2jUg~1d696d2901564d2c7a1041c377d3b216

Analyst Recommendations on Lipella Pharmaceuticals Inc.

Maxim Initiates Lipella Pharmaceuticals at Buy Rating With $2 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.7624 USD
Average target price
2 USD
Spread / Average Target
+162.32%
High Price Target
2 USD
Spread / Highest target
+162.32%
Low Price Target
2 USD
Spread / Lowest Target
+162.32%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Lipella Pharmaceuticals Inc.

Maxim

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. LIPO Stock
  4. Consensus Lipella Pharmaceuticals Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW